25 Jan 2019

Transparency notification BlackRock, Inc.

Read More
16 Jan 2019

UCB and Amgen Receive Positive Vote From FDA Advisory Committee In Favor of Approval For EVENITY™ (Romosozumab) 

Read More
8 Jan 2019

EVENITY® (romosozumab) Receives Approval In Japan for the Treatment of Osteoporosis In Patients at High Risk of Fracture

Read More
8 Jan 2019

Transparency notification UCB SA/NV

Read More
30 Dec 2018

Transparency notifications BlackRock, Inc.

Read More
12 Dec 2018

Transparency notifications BlackRock, Inc.

Read More
2 Dec 2018

UCB announces approval of VIMPAT® in China

Read More
30 Nov 2018

UCB and Amgen Announce FDA Advisory Committee Meeting to review EVENITY™ (Romosozumab) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture

Read More
30 Nov 2018

UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership 

Read More
21 Nov 2018

Transparency notifications BlackRock, Inc.

Read More
Subscribe to